Estimated 300,000 people in UK have potentially fatal heart valve disease

heart
Credit: CC0 Public Domain

An estimated 300,000 people in the UK have aortic valve stenosis, a progressive and potentially fatal condition, suggests research published in the open access journal Open Heart.

The UK health service will struggle to cope with the sheer number of people needing treatment for this over the next few years, with the number set to rise further as the population ages, warn the researchers.

What’s more, over half of those with advanced disease will likely die within 5 years without timely, proactive treatment, they add.

Aortic stenosis occurs when the aortic valve, the main outflow valve of the heart, stiffens and narrows. This means it can no longer open fully, reducing or blocking blood flow from the heart into the main artery (aorta) and the rest of the body.

In a significant portion of people the condition remains silent, with symptoms appearing only when the condition is already advanced.

Given the aging of the UK population, it is thought that there may be a large pool of as yet undiagnosed people who might benefit from life-saving treatment.

The researchers therefore set out to provide informed estimates of the overall prevalence of severe aortic stenosis across the UK and how many people might benefit from surgery: surgical aortic valve replacement (SAVR) or transcatheter implant (TAVI).

To guage the numbers potentially at risk of aortic stenosis, the researchers obtained national age and sex-specific population data for the year 2019, when nearly a third (30%; 20.1 million) of the UK’s 66 million population were aged 55 and older.

To come up with valid and accurate age specific prevalence estimates, they drew on data from one of the largest ever studies of the condition to date (NEDA study). This had come up with a prevalence of severe disease of 3.5% among the over 75s.

Using this as a reference point, they estimated the prevalence of severe aortic stenosis as 1.2% among 70–74 year olds; 0.7% among 65–69 year olds; 0.5% among 60–64 year olds; and 0.4% among 55–59 year olds in 2019.

They then estimated the proportions of those with and without symptoms, and of those with symptoms, how many could be managed with drugs and how many would need surgery, based on historical treatment patterns.

And they calculated how many people would die, if left untreated, based on the estimated total numbers of people diagnosed with the condition in 2019, and actual 5-year death rates observed among the untreated in the NEDA study.

Based on all these figures, the researchers estimate that the overall prevalence of severe aortic stenosis among the over 55s in the UK in 2019 to be almost 1.5%, equal to around 300,000 people living with this potentially deadly condition at any one time.

Of the total numbers with aortic stenosis, just under 200,000 (68%) had severe (symptomatic) disease in 2019, prompting the need for around 116,000 SAVR and 51,000 TAVI procedures, the researchers estimate.

But the 92,389 people with ‘silent’ disease, representing nearly a third of all cases (32%), will probably not be diagnosed unless they are being proactively screened for aortic stenosis or undergoing tests for another heart problem, they suggest.

Without timely proactive treatment up to 172,859 of those with severe aortic stenosis (59%, overall) in 2019 will die over the next five years to 2024, equal to 35,000 people every year.

Nearly 10,000 of these deaths (almost 6% of all cases) will be among 55–64 year olds, with an additional 29,548 deaths (17%) among 65–74 year olds. Most deaths will occur in 75–84 year olds (86,383; 50%) and the over 85s (47,121; 27%), the researchers estimate.

Based on their estimates, the researchers question whether the UK health service will be able to cope with the prevalence of aortic disease over the next few years.

“Critically, such an indicative burden is far greater than the current capacity within the NHS to screen, detect, triage and treat such cases,” with the prevalence increasing further as the population ages, they warn.

“There seems little doubt, therefore, that there is a significant shortfall between interventions undertaken for severe [aortic stenosis] and our estimates of potential demand.”

The researchers acknowledge that they have no way of verifying their estimates, and advise that population data on the incidence and prevalence of aortic stenosis in the UK are inadequate, so their findings should be interpreted cautiously.

But their figures are in line with those in the few available previously published studies, they point out.

“In conclusion, this study suggests that severe [aortic stenosis] is a common condition affecting many individuals within the UK population aged 55 [and older]. Without appropriate detection and intervention, their survival prospects are likely to be poor.”



More information:
Uncovering the treatable burden of severe aortic stenosis in the UK, Open Heart, DOI: 10.1136/openhrt-2021-001783

Citation:
Estimated 300,000 people in UK have potentially fatal heart valve disease (2022, January 25)
retrieved 12 February 2022
from https://medicalxpress.com/news/2022-01-people-uk-potentially-fatal-heart.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
DJ Temba Bavuma rocks party till Sunrise(rs) thumbnail

DJ Temba Bavuma rocks party till Sunrise(rs)

South Africa and Sunrisers Eastern Cape batter Temba Bavuma won the SA20 title in 2024 SA20 FinalBavuma, who did not play in the final of the tournament, took charge of the afterparty SA20 FinalBavuma was seen in his new avatar DJ-ing at the party SA20 FinalSunrisers defeated Durban Super Giants in the final of the
Read More
IV Hyperimmune Immunoglobulin No Help in Severe COVID thumbnail

IV Hyperimmune Immunoglobulin No Help in Severe COVID

Hyperimmune intravenous immunoglobulin (hIVIG) added to standard of care, including remdesivir (Veklury), did not improve clinical outcomes among hospitalized patients with severe COVID-19, a randomized trial found. People given hIVIG had no better chance of a better clinical outcome at day 7 compared with those assigned placebo (adjusted OR 1.06, 95% CI 0.77-1.45), reported Mark…
Read More
סיכון של 15%-20% למי שייצא מהבידוד המקוצר להיות מידבק thumbnail

סיכון של 15%-20% למי שייצא מהבידוד המקוצר להיות מידבק

החל מהיום (ד') נכנס לתוקף קיצור הבידוד לחמישה ימים למאומתים וללא מחוסנים שנחשפו למאומת. זאת, לצד נתון שמסר הבוקר בראיון לגל"צ מנכ"ל משרד הבריאות, פרופ' נחמן אש, על 71 אלף מאומתים חדשים בישראל, נכון לאתמול. החלטת שר הבריאות ניצן הורוביץ על קיצור הבידוד עוררה ביקורת קשה מצד מומחים שונים שטוענים כי התקבלה בפזיזות וללא התייעצות…
Read More
Walgreens pays $100 million to settle class action drug case thumbnail

Walgreens pays $100 million to settle class action drug case

Photo: Joe Raedle/Getty ImagesWalgreens is paying $100 million to settle a seven-year-old class action lawsuit alleging the company inflated drug prices. Walgreens denies wrongdoing. The class action suit, Russo v. Walgreens Co., dragged out over seven years in "hard-fought litigation," according to court documents. WHY THIS MATTERS Walgreens did not consider the prices it charged
Read More
COVID-19, cold, allergies and the flu: What are the differences? thumbnail

COVID-19, cold, allergies and the flu: What are the differences?

COVID-19, cold, allergies and the flu: What are the differences?COVID-19, the common cold, seasonal allergies and the flu have many similar signs and symptoms. Find out about some of the important differences between these illnesses.By Mayo Clinic Staff If you have signs or symptoms of coronavirus disease 2019 (COVID-19), it's important that you contact your…
Read More
Index Of News
Total
0
Share